ArticleDrug and alcohol dependence2022
Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder.
Article in Drug and alcohol dependence, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 98 citations in OpenAlex.
- The impact of the communities that HEAL intervention on the provision of jail-based medication for opioid use disorder & linkage programs at release: Results from a randomized, wait-list controlled trial.Journal of substance use and addiction treatment · 2026Trial
- Outcomes following two models of treatment linkage facilitation for women with a history of OUD following jail release.Journal of substance use and addiction treatment · 2025Trial
- Assessing the comparative effectiveness of ECHO and coaching implementation strategies in a jail/provider MOUD implementation trial.Implementation science : IS · 2025Trial
- Patient preferences for medications to treat opioid use disorder in carceral settings: Implications for tailored implementation and service delivery.Journal of substance use and addiction treatment · 2026Article
- "So what's gonna happen when I get out of here?" Qualitative barriers and facilitators to MOUD continuity post-release from jail.Drug and alcohol dependence · 2026Article
- Too many for too long: physicians dismantling mass incarceration.Health & justice · 2026Review
- The Portuguese police experience with drug decriminalisation.Policing & society · 2026Article
- "Talk About It!" Shared Decision-Making for Methadone and Buprenorphine Initiation: Development and Preliminary Evaluation of a Conversation Aid via Community-Based Participatory Research.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2026Article
- Structural and Policy Determinants of Access to Medications for Opioid Use Disorder Among Pregnant People in U.S. Jails.International journal of environmental research and public health · 2026Article
- A mixed methods analysis of clinics' perspectives on community factors influencing access to medications for opioid use disorder.Addiction science & clinical practice · 2026Article
- The Socioeconomic Impact of Long-Acting Injectable Buprenorphine.ClinicoEconomics and outcomes research : CEOR · 2026Article
- Allocative efficiency of opioid overdose prevention strategies for people incarcerated in New Jersey.Harm reduction journal · 2025Article
- Dissemination and diffusion of research to address the opioid crisis in justice settings: a Justice Community Opioid Innovation Network (JCOIN) case study.Research square · 2025Article
- A qualitative study of police officers' knowledge of the relationship between police opioid seizures and subsequent risk of overdose.Health & justice · 2025Article
- Medications for Opioid Use Disorder in County Jails - Outcomes after Release.The New England journal of medicine · 2025Observational
- Injectable buprenorphine during transition out of prison: A pilot partially randomized preference trial protocol.Contemporary clinical trials · 2025Article
- A mixed-method exploratory assessment of provider-based stigma of opioid use disorder (OUD) and support for medications for opioid use disorder (MOUD) in carceral settings.Harm reduction journal · 2025Article
- Access to and predictors of substance use treatment and support among people experiencing incarceration in the United States: Analysis of a national cross-sectional study.Drug and alcohol dependence reports · 2025Article
- Medication for opioid use disorder service delivery in carceral facilities: update and summary report.Health & justice · 2025Review
- Medications for opioid use disorders among incarcerated persons and those in the community supervision setting: exploration of implementation issues with key stakeholders.Addiction science & clinical practice · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundBuprenorphine is an effective medication for opioid use disorder (MOUD) when offered in community-based settings, but evidence is limited for incarcerated populations, particularly in relation to recidivism. In Massachusetts, Franklin County jail (FCSO) was among the first to provide buprenorphine; adjacent Hampshire County jail (HCHC) offered it more recently. These jails present a natural experiment to determine whether outcomes are different between individuals who did and did not have the opportunity to receive buprenorphine in jail.
methodsWe examined outcomes of all incarcerated adults with opioid use disorder (n = 469) who did (FCSO n = 197) and did not (HCHC n = 272) have the opportunity to receive buprenorphine. The primary outcome was post-release recidivism, defined as time from jail exit to a recidivism event (incarceration, probation violation, arraignment). Using Cox proportional hazards models, we investigated site as a predictor, controlling for covariates. We also examined post-release deaths.
resultsFewer FCSO than HCHC individuals recidivated (48.2% vs. 62.5%; p = 0.001); fewer FCSO individuals were re-arraigned (36.0% vs. 47.1%; p = 0.046) or re-incarcerated (21.3% vs. 39.0%; p < 0.0001). Recidivism risk was lower in the FCSO group (hazard ratio 0.71, 95% confidence interval 0.56, 0.89; p = 0.003), net of covariates (adjusted hazard ratio 0.68, 95% confidence interval 0.53, 0.86; p = 0.001). At each site, 3% of participants died.
conclusionsAmong incarcerated adults with opioid use disorder, risk of recidivism after jail exit is lower among those who were offered buprenorphine during incarceration. Findings support the growing movement in jails nationwide to offer buprenorphine and other agonist medications for opioid use disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.